Both studies demonstrated that treatment with DNA-PKC inhibitors alleviated the severity of asthma-associated symptoms, possibly because of their ability to reduce NHEJ repair activity, which exerts an immunosuppressive effect, leading to decreased sensitization. Here, PRRT2 is linked to asthma.